NO20074613L - Tricykliske nukleosidforbindelser for behandling av virale infeksjoner - Google Patents

Tricykliske nukleosidforbindelser for behandling av virale infeksjoner

Info

Publication number
NO20074613L
NO20074613L NO20074613A NO20074613A NO20074613L NO 20074613 L NO20074613 L NO 20074613L NO 20074613 A NO20074613 A NO 20074613A NO 20074613 A NO20074613 A NO 20074613A NO 20074613 L NO20074613 L NO 20074613L
Authority
NO
Norway
Prior art keywords
treatment
viral infections
nucleoside compounds
tricyclic nucleoside
tricyclic
Prior art date
Application number
NO20074613A
Other languages
English (en)
Inventor
Xiaoling Zheng
Christopher Don Roberts
Choung U Kim
Ronald Conrad Griffith
Jesse D Keicher
Sebastian Johannes Reinh Liehr
Vivek Kumar Rajwanshi
Marija Prhavc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NO20074613L publication Critical patent/NO20074613L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Beskrevet er tricykliske nukleosid forbindelser med formel (I) og fremgangsmåter derav for behandling av virale infeksjoner mediert i det minste delvis av et Flaviviridae familie virus.
NO20074613A 2005-02-28 2007-09-11 Tricykliske nukleosidforbindelser for behandling av virale infeksjoner NO20074613L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65746305P 2005-02-28 2005-02-28
PCT/US2006/007132 WO2006093987A1 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections

Publications (1)

Publication Number Publication Date
NO20074613L true NO20074613L (no) 2007-11-27

Family

ID=36570903

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20074613A NO20074613L (no) 2005-02-28 2007-09-11 Tricykliske nukleosidforbindelser for behandling av virale infeksjoner
NO20074915A NO20074915L (no) 2005-02-28 2007-09-27 Tricykliske-nukleosid promedikamenter for behandling av virale infeksjoner

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20074915A NO20074915L (no) 2005-02-28 2007-09-27 Tricykliske-nukleosid promedikamenter for behandling av virale infeksjoner

Country Status (18)

Country Link
US (4) US7534771B2 (no)
EP (2) EP1853617A1 (no)
JP (2) JP2008531704A (no)
KR (2) KR20070106781A (no)
CN (2) CN101128474A (no)
AP (2) AP2007004128A0 (no)
AR (1) AR058419A1 (no)
AU (2) AU2006218704A1 (no)
BR (2) BRPI0607770A2 (no)
CA (2) CA2597685A1 (no)
EA (2) EA200701850A1 (no)
HR (2) HRP20070435A9 (no)
IL (2) IL184954A0 (no)
MX (2) MX2007010460A (no)
NO (2) NO20074613L (no)
TW (1) TW200640474A (no)
WO (2) WO2006093986A1 (no)
ZA (1) ZA200707410B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060123707A (ko) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
BRPI0607770A2 (pt) * 2005-02-28 2009-06-13 Genelabs Tech Inc compostos de nucleosideo tricìclico para tratamento de infecções virais
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
GB0718575D0 (en) * 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
CL2009002206A1 (es) * 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
GB0900914D0 (en) * 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8343983B2 (en) * 2009-03-31 2013-01-01 Arqule, Inc. Substituted pyrazolo-pyrimidine compounds
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
JP2014520772A (ja) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ Ｈｃｖ併用療法
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2639238A1 (en) * 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE69133617D1 (de) * 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2159639A1 (en) 1993-04-02 1994-10-13 Vincent J. Miles Method for selective inactivation of viral replication
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
CA2233309A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
AU726374B2 (en) * 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
WO1998043991A1 (en) 1997-04-02 1998-10-08 Amersham Pharmacia Biotech Uk Limited Tricyclic base analogues
DE69838513T2 (de) 1997-12-11 2008-07-03 Smithkline Beecham Corp. Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
BRPI0419345B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc uso do (2’r)-2’-desoxi-2’-flúor-2’-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
KR20060123707A (ko) * 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1680436A1 (en) * 2003-10-27 2006-07-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
BRPI0607770A2 (pt) * 2005-02-28 2009-06-13 Genelabs Tech Inc compostos de nucleosideo tricìclico para tratamento de infecções virais

Also Published As

Publication number Publication date
EP1853618A1 (en) 2007-11-14
US7524825B2 (en) 2009-04-28
WO2006093986A1 (en) 2006-09-08
CN101142226A (zh) 2008-03-12
KR20070106781A (ko) 2007-11-05
CA2597685A1 (en) 2006-09-08
MX2007010460A (es) 2007-11-08
AU2006218704A1 (en) 2006-09-08
BRPI0607769A2 (pt) 2009-10-06
AP2007004118A0 (en) 2007-08-31
HRP20070435A2 (hr) 2008-02-29
BRPI0607770A2 (pt) 2009-06-13
NO20074915L (no) 2007-11-20
AU2006218705A1 (en) 2006-09-08
EA200701849A1 (ru) 2008-02-28
JP2008531704A (ja) 2008-08-14
EP1853617A1 (en) 2007-11-14
CN101128474A (zh) 2008-02-20
HRP20070435A9 (en) 2008-09-30
MX2007010463A (es) 2007-11-08
AP2007004128A0 (en) 2007-08-31
AR058419A1 (es) 2008-02-06
KR20070106767A (ko) 2007-11-05
HRP20070436A2 (hr) 2008-02-29
IL184955A0 (en) 2007-12-03
US7534771B2 (en) 2009-05-19
US20090208457A1 (en) 2009-08-20
WO2006093987A1 (en) 2006-09-08
US20060252715A1 (en) 2006-11-09
EA200701850A1 (ru) 2008-02-28
JP2008531703A (ja) 2008-08-14
IL184954A0 (en) 2007-12-03
ZA200707410B (en) 2008-10-29
US20060194749A1 (en) 2006-08-31
US20090253648A1 (en) 2009-10-08
CA2597683A1 (en) 2006-09-08
TW200640474A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
HRP20070435A2 (hr) Triciklički nukleozidni spojevi za liječenje virusnih infekcija
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
TW200720285A (en) Nucleoside compounds for treating viral infections
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
SG164376A1 (en) Hcv ns3 protease inhibitors
TW200730478A (en) N-(6-membered aromatic ring)-amido anti-viral compounds
CY1111423T1 (el) Αναστολεις ns5b hcv
TW200730476A (en) N-(5-membered aromatic ring)-amido anti-viral compounds
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
NO20084637L (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
EA201000051A1 (ru) Противовирусные соединения, композиции и способы использования
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
NO20073105L (no) Pyridazinonforbindelser
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
WO2008008907A3 (en) Antiviral agents
TW200726471A (en) Heteroaryl derivatives for treating viruses
TW200631585A (en) 5-nitro-nucleoside compounds for treating viral infections
UA90909C2 (en) Hcv ns3 protease inhibitors
UA95990C2 (en) Hcv ns3 protease inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application